Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Clin Breast Cancer. 2020 Oct 5;21(3):199–204. doi: 10.1016/j.clbc.2020.09.015

Table 2.

Treatment Response for 31 Evaluable Patients

%
ORR (CR + PR)
 Whole cohort (14/31) 45.16 (95% CI, 29.2–62.2)
 HR+/HER2− (9/17) 52.94
 TNBC (5/14) 35.71
CR rate
 Whole cohort (3/31) 9.68 (95% CI, 3.4–24.9)
 HR+/HER2− (2/17) 11.76
 TNBC (1/14) 7.14
CBR (CR + PR + SD)
 Whole cohort (23/31) 74.19 (95% CI, 56.8–86.3)
 HR+/HER2− (15/17) 88.24
 TNBC (8/14) 57.14

Abbreviations: CBR = clinical benefit rate; CI = confidence interval; CR = complete response; HER2− = Human epidermal growth factor receptor 2-negative; HR+ = hormone receptor-positive; ORR = overall response rate; PR = partial response; SD = stable disease; TNBC = triple negative breast cancer.